Clinical Trials

A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Cancer Type

Chronic Lymphoid Leukemia, Lymphoma

ClinicalTrials.gov Identifier

NCT05512390

Principal Investigator

Daruka Mahadevan, MD, PhD

For more information about this study
View Details

About This Study

M22-716 is a Phase 1, FIH, open-label, dose escalation, dose expansion, biomarker/pharmacodynamic (PD) study of ABBV-319 in participants with relapsed or refractory (R/R) B-cell malignancies.